Anavex Life Sciences reports results for Alzheimer’s drug in Phase IIb/III trial
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company, has presented groundbreaking results from its Phase IIb/III trial of blarcamesine (Anavex 2-73) for treatment of early Alzheimer’s disease at the 2024…
